Education
About Us
Working with TipRanks
Follow Us
Apogee Therapeutics, Inc. (APGE)
:APGE
APGE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$26.20 - $63.50
Previous CloseN/A
Volume109.80K
Average Volume (3M)848.85K
Market Cap
$1.78B
Enterprise Value$2.19B
Total Cash (Recent Filing)$151.89M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.61
Next Earnings
May 19, 2025EPS Estimate
-1.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.23
Shares Outstanding46,016,540
10 Day Avg. Volume939,702
30 Day Avg. Volume848,845
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-10.09
Forecast
1Y Price Target
$93.63Price Target Upside212.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Apogee Therapeutics News
PremiumCompany Announcements
Apogee Therapeutics Reports 2024 Financial Results and Pipeline Progress
PremiumCompany Announcements
Apogee Therapeutics Reports Positive Phase 1 Results---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe first atopic dermatitis efficacy data for APG777 is likely the biggest driver for shares, with potential upside if efficacy exceeds prior benchmarks.
Competitive AdvantageThe developments favor APG990, which binds an OX40L epitope, suggesting a competitive advantage for Apogee Therapeutics.
Financial StabilityAPGE has $731.1 million in cash, cash equivalents, and marketable securities, expected to fund operations into the first quarter of 2028, providing financial stability.
Bears Say
Conflict Of InterestInvestors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report.
Safety ConcernsSafety remains a negative differentiator for rocatinlimab, with new data disclosing pyrexia and chills rates consistent with prior rates.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
APGE FAQ
What was Apogee Therapeutics, Inc.’s price range in the past 12 months?
Apogee Therapeutics, Inc. lowest stock price was $26.20 and its highest was $63.50 in the past 12 months.
What is Apogee Therapeutics, Inc.’s market cap?
Apogee Therapeutics, Inc.’s market cap is $1.78B.
When is Apogee Therapeutics, Inc.’s upcoming earnings report date?
Apogee Therapeutics, Inc.’s upcoming earnings report date is May 19, 2025 which is in 36 days.
How were Apogee Therapeutics, Inc.’s earnings last quarter?
Apogee Therapeutics, Inc. released its earnings results on Mar 03, 2025. The company reported -$1.178 earnings per share for the quarter, beating the consensus estimate of -$1.189 by $0.011.
Is Apogee Therapeutics, Inc. overvalued?
According to Wall Street analysts Apogee Therapeutics, Inc.’s price is currently Undervalued.
Does Apogee Therapeutics, Inc. pay dividends?
Apogee Therapeutics, Inc. does not currently pay dividends.
What is Apogee Therapeutics, Inc.’s EPS estimate?
Apogee Therapeutics, Inc.’s EPS estimate is -1.24.
How many shares outstanding does Apogee Therapeutics, Inc. have?
Apogee Therapeutics, Inc. has 46,016,540 shares outstanding.
What happened to Apogee Therapeutics, Inc.’s price movement after its last earnings report?
Apogee Therapeutics, Inc. reported an EPS of -$1.178 in its last earnings report, beating expectations of -$1.189. Following the earnings report the stock price went down -0.159%.
Which hedge fund is a major shareholder of Apogee Therapeutics, Inc.?
Currently, no hedge funds are holding shares in APGE
---
Apogee Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$93.63 (212.73% Upside)
$93.63 (212.73% Upside)
Blogger Sentiment
Bullish
APGE Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $990.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.21%
12-Months-Change
Fundamentals
Return on Equity
-33.22%
Trailing 12-Months
Asset Growth
87.83%
Trailing 12-Months
Company Description
Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
---
APGE Stock 12 Month Forecast
Average Price Target
$93.63
▲(212.73% Upside)
Technical Analysis
Ligand Pharma
―
Tarsus Pharmaceuticals
―
Belite Bio, Inc. ADR
―
Biohaven Ltd.
―
Ascentage Pharma Group International Unsponsored ADR
―
Best Analysts Covering APGE
1 Year
1 Year Success Rate
3/5 ratings generated profit
1 Year Average Return
+17.26%
reiterated a buy rating last month
Copying Seamus Fernandez's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +17.26% per trade.
---